• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Letter to the Editor regarding Response to "Letter to Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19".致编辑的信：关于对《致编辑的信：恩昔洛韦在降低 COVID-19 高危门诊患者严重结局方面的真实世界有效性》的回复
Infect Dis Ther. 2024 Nov;13(11):2463-2467. doi: 10.1007/s40121-024-01054-6. Epub 2024 Sep 27.
2
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19.恩昔瑞韦对降低COVID-19高风险门诊患者严重结局的真实世界有效性
Infect Dis Ther. 2024 Aug;13(8):1821-1833. doi: 10.1007/s40121-024-01010-4. Epub 2024 Jun 28.
3
Letter to the Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19".致编辑的信：“恩昔瑞韦在降低COVID-19高风险门诊患者严重结局方面的真实世界有效性”
Infect Dis Ther. 2024 Nov;13(11):2461-2462. doi: 10.1007/s40121-024-01053-7. Epub 2024 Sep 24.
4
Treatment with ensitrelvir for COVID-19 in hospitalized patients of very advanced age: Case series.在非常高龄的住院 COVID-19 患者中使用恩赛特韦治疗：病例系列。
Medicine (Baltimore). 2024 Jul 26;103(30):e39080. doi: 10.1097/MD.0000000000039080.
5
Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review.恩赛特韦在 SARS-CoV-2 患者中的应用：一项回顾性图表研究。
J Infect Chemother. 2024 Sep;30(9):946-950. doi: 10.1016/j.jiac.2024.02.015. Epub 2024 Feb 15.
6
Real-World Efficacy of Ensitrelvir in Hospitalized Patients With COVID-19 in Japan: A Retrospective Observational Study.恩西他韦在日本新冠肺炎住院患者中的真实世界疗效：一项回顾性观察研究。
Cureus. 2024 May 25;16(5):e61048. doi: 10.7759/cureus.61048. eCollection 2024 May.
7
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.一项评估新型口服 SARS-CoV-2 3CL 蛋白酶抑制剂恩赛特韦（ensitrelvir）在日本轻至中度 COVID-19 或无症状 SARS-CoV-2 感染患者中的疗效和安全性的随机 2/3 期研究：2a 期部分结果。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0069722. doi: 10.1128/aac.00697-22. Epub 2022 Sep 13.
8
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.口服恩赛特韦 5 天治疗轻中度 COVID-19 患者的疗效和安全性：SCORPIO-SR 随机临床试验。
JAMA Netw Open. 2024 Feb 5;7(2):e2354991. doi: 10.1001/jamanetworkopen.2023.54991.
9
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial.在 3 期 SCORPIO-SR 试验中，早期使用恩赛特韦治疗预防新冠后状况。
Antiviral Res. 2024 Sep;229:105958. doi: 10.1016/j.antiviral.2024.105958. Epub 2024 Jul 6.
10
Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial.依特司韦单抗治疗无症状或轻度 COVID-19 的疗效和安全性：一项多中心、随机、2b/3 期临床研究的探索性分析。
Influenza Other Respir Viruses. 2024 Jun;18(6):e13338. doi: 10.1111/irv.13338.

本文引用的文献

1
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19.恩昔瑞韦对降低COVID-19高风险门诊患者严重结局的真实世界有效性
Infect Dis Ther. 2024 Aug;13(8):1821-1833. doi: 10.1007/s40121-024-01010-4. Epub 2024 Jun 28.
2
Clinical course and management of COVID-19 in the era of widespread population immunity.广泛人群免疫时代下的 COVID-19 临床病程和管理。
Nat Rev Microbiol. 2024 Feb;22(2):75-88. doi: 10.1038/s41579-023-01001-1. Epub 2023 Dec 19.
3
Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022.帕克洛维德降低 COVID-19 成年患者住院率-美国，2022 年 4 月-9 月。
MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1531-1537. doi: 10.15585/mmwr.mm7148e2.
4
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge.奈玛特韦利特的使用与奥密克戎疫情期间的严重新冠结局。
N Engl J Med. 2022 Sep 1;387(9):790-798. doi: 10.1056/NEJMoa2204919. Epub 2022 Aug 24.
5
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.帕克洛维德降低高危患者的严重 2019 冠状病毒病和死亡率的有效性。
Clin Infect Dis. 2023 Feb 8;76(3):e342-e349. doi: 10.1093/cid/ciac443.

Letter to the Editor regarding Response to "Letter to Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19".

作者信息

Takazono Takahiro, Fujita Satoki, Komeda Takuji, Miyazawa Shogo, Yoshida Yuki, Kitanishi Yoshitake, Kinoshita Masahiro, Kojima Satoshi, Shen Huilian, Uehara Takeki, Hosogaya Naoki, Iwanaga Naoki, Mukae Hiroshi

机构信息

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Data Science Department, Shionogi & Co., Ltd., Osaka, Japan.

出版信息

Infect Dis Ther. 2024 Nov;13(11):2463-2467. doi: 10.1007/s40121-024-01054-6. Epub 2024 Sep 27.

DOI:10.1007/s40121-024-01054-6
PMID:39331323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11499536/
Abstract
摘要